Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Biotechnology

Healthcare
$1.72 -2.64%

-$0.05 today

Market cap
$765.80M
Beta
1.07
P/E (TTM)
-30.5
EPS (TTM)
-$0.07
52W Low $0.71High $2.53

Volume 2.02M

Average 2.48M

LXRX Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Lexicon Pharmaceuticals, Inc.NASDAQ: LXRX

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $21.1M rose 1572.1% year over year, ahead of the +123.1% change in trailing-twelve-month revenue. Sequentially, it rose 284.2% from the prior quarter. Over 3 fiscal years it compounded at +610.3% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $37.4M (-24.9%) for the fiscal year ending Dec 2026, a slowdown from the +60.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$21.1M+284.2% QoQ
Last fiscal yearDec 2025
$49.8M+60.2% YoY
LTMMar 2026
$69.64M+123.1% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1572.1%-86.2%-1658.3 pp
1 year+60.2%-24.9%-85.1 pp
3-year CAGR+610.3%+15.0%-595.2 pp
5-year CAGR+39.1%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
49.8M USD
Year-over-year change
+60.2%
4-year CAGR
+259.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How LXRX compares with its peers on the latest reported figures

  • LXRX's LTM Mar 2026 revenue of $69.64M is the 6th highest of the 11 companies compared; the peer median is $153.44M.
  • Its year-over-year change of +123.1% is the 2nd highest of 7, against a peer median of +34.4%.
  • Over three fiscal years its annual growth of +610.3% compares with a peer median of +41.6%.
LXRX Competitors Peer median
Revenue for LXRX and competitors
Company Period LTM YoY 3-year CAGR
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.01B -42.8%+35.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$959.76M -0.7%+17.1%
BCRXBioCryst Pharmaceuticals, Inc.LTM Jun 2026$940.61M +68.7%+47.8%
MNKDMannKind CorporationLTM Mar 2026$360.78M +21.2%+51.8%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$299.77M +47.6%+34.8%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$69.64M +123.1%+610.3%
OVIDOvid Therapeutics Inc.LTM Mar 2026$7.12M +1199.6%+69.0%
TRVITrevi Therapeutics, Inc.LTM Sep 2026$0 ——
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 ——
DMACDiaMedica Therapeutics Inc.LTM Mar 2026$0 ——
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$0 ——
Peer median (excluding LXRX) $153.44M+34.4%+41.6%

Competitors are the stored peer set for LXRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue298K139K1.2M31.08M49.8M
Cost of Revenue55.05M52.52M58.97M616K274K
Gross Profit(54.75M)(52.38M)(57.77M)30.47M49.53M
Gross Margin-18371.8%-37681.3%-4798.0%98.0%99.4%
Research & Development55.05M52.82M58.89M84.48M61.12M
Selling, General & Admin000131.9M37.32M
Operating Expenses32.34M48.38M113.98M227.58M98.44M
Depreciation & Amortization292K427K554K534K621K
EBITDA(86.66M)(100.03M)(169.76M)(184.29M)(41.38M)
EBITDA Margin-29081.9%-71966.2%-14099.3%-592.9%-83.1%
Operating Income(87.09M)(100.76M)(171.75M)(197.12M)(48.91M)
Operating Margin-29224.8%-72489.2%-14265.0%-634.2%-98.2%
Interest Income134K1.6M7.73M12.29M6.91M
Interest Expense802K2.78M13.1M15.58M8.34M
Other Income / Expenses(668K)(1.18M)(5.37M)(3.29M)(1.43M)
Income Before Tax(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Pre-Tax Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
Income Tax Expense00000
Net Income(87.76M)(101.94M)(177.12M)(200.4M)(50.34M)
Net Margin-29449.0%-73341.0%-14710.9%-644.8%-101.1%
EPS (Basic)(0.61)(0.62)(0.80)(0.63)(0.14)
EPS (Diluted)(0.61)(0.62)(0.80)(0.63)(0.14)
Weighted Avg Shares145.65M165.73M221.13M320.03M363.05M
Weighted Avg Shares (Diluted)145.65M165.73M221.13M320.03M363.05M

Lexicon Pharmaceuticals, Inc.

NASDAQ:LXRX

Intrinsic Alpha fair value

Locked

Current Price

$1.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.